Cystic neoplasms of the pancreas encompass a heterogeneous group of lesions ranging from benign entities to precursors of invasive carcinoma. Key subtypes include serous cystic neoplasms, mucinous ...

Servier today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to ...

Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) of the Tumorad-01 study declared that a primary endpoint, identifying the maximum tolerated dose, has ...

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027Hosting virtual ...

SIM0505/CDH6 ADC dose optimization initiated in gynecologic cancersSIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026 LNCB74 ...

Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow. Read why I rate KRYS ...

Krystal Biotech KRYS reported first-quarter 2026 earnings per share (EPS) of $1.83, which surpassed the Zacks Consensus ...

Let this be a lesson to always advocate for yourself at the doctor, and if you're getting ignored, get a second opinion.

LUND, SE / ACCESS Newswire / May 7, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)JANUARY - MARCH IN BRIEFNet sales for the quarter amounted to KSEK 22 (KSEK 338)The loss for the quarter amounted ...

Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) registrational ...

Breakthrough therapy designation targets an unmet-need ACC population, positioning B7-H4 as a therapeutically actionable antigen in solid histology or high-grade transformed disease. Dose-escalation ...

Revolution Medicines’ stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul.